Six patients with chronic renal failure (CRF group) and four healthy subjects (HS group) were given 5 mg oral and intravenous doses of bumetanide in a random, crossover design. The CRF group had significantly lower plasma and renal clearances, resulting in a five-to sixfold reduction in the fractional urinary excretion of the drug. The percent free drug in plasma for the CRF group was more than double that for the HS group, and significant correlations were observed for volume of distribution at steady state vs. percent free (r = 0.661; P < 0.05), nonrenal clearance vs. percent free (r = 0.796; P < 0.01), and renal clearance vs. creatinine clearance (r = 0.995; P < 0.001). Although bioavailability was relatively consistent among the HS (0.664 ± 0.112) and CRF (0.689 ± 0.149) groups, the absorption-time profiles were more irregular for both groups. Cumulative sodium excretion and overall efficiency of response to bumetanide did not differ significantly between the two routes of administration in either group. ( 
Bumetanide
(3-n-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid) is a potent loop diuretic that is similar to furosemide with respect to its pharmacologic action and clinical indications.' Its principal site of action is the thick ascending limb of the loop of Henle, [2] [3] [4] where it has been shown to exert its natriuretic and diuretic effects from the luminal surface of the nephron.4 Because bumetanide is highly protein bound,5-7 glomerular filtration is a minor mechanism for drug excretion. Instead, bumetanide gains access to the kidney lumen through the nonspecific organic acid secretory pathway.8-1° As a result, any pathophysiologic condition that affects the renal tubular secretion of bumetanide can thereby modify its dose-response relationship. Table I . Clinical data of healthy subjects and patients with CRF *Determined over 24 hours.
tamed from Hoffmann-La Roche, Inc. All other chemicals and solvents were reagent grade or better, as previously reported 21 Study participants. This study was performed in the Clinical Research Center of the University of Michigan Hospitals. The control group consisted of four healthy subjects, as judged by medical history, physical examination, and standard laboratory tests, including a creatinine clearance determination (Table I ). The patient group consisted of six individuals with moderate to severe CRF and a stable creatinine clearance (CI,cR) of <30 ml/min (Table I) . Patients were excluded from the study if they had diabetes or signs or symptoms of hepatic, hematologic, or gastrointestinal diseases. All diuretics were withheld for 24 hours before each study day and drugs that have diuretic-like properties (i.e., theophylline) or that may inhibit the diuretic response (i.e., nonsteroidal anti-inflammatory drugs) were not allowed for a minimum of 3 days before bumetanide administration. Patients were instructed to adhere strictly to their prescribed dietary restrictions and each participant was asked to avoid caffeine-containing beverages throughout the study. All participants were fully informed of the nature of the study and signed an informed consent form approved by the Committee to CLIN PHARMACOL THER JUNE 1986 Review Grants for Clinical Research and Investigation Involving Human Beings of the University of Michigan Medical Center. Study design. After an overnight fast, each participant received a 5 mg dose of bumetanide, either orally (five tablets) or intravenously, at 8 AM in a randomized crossover design. A period of at least 1 week elapsed between the two dosing regimens. Bumetanide tablets were taken with 8 oz water; the solution was infused at a constant rate over 3 minutes. For the intravenous dose, serial blood samples (3 ml) were drawn from the contralateral arm through an indwelling heparinized (10 U/ml) scalp vein needle and drawn into tubes containing EDTA at 0, 3, 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 , and 1440 minutes after the start of the infusion. For the oral dose, serial blood samples were drawn at 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 420, 480 , and 1440 minutes after drug dosing. Blood samples were centrifuged immediately and the plasma was harvested and frozen.
Voided urine was collected from 24 to 0 (blank), 0 to 0.5, 0.5 to 1.0, 1.0 to 1.5, 1.5 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, and 8 to 24 hours relative to drug dosing. Plasma and urine samples were stored at 20° C until subsequent where T is the constant-rate infusion time and C, is the coefficient of the ith exponential term for bolus intravenous data, Eq. 1 can be rearranged to the corresponding equation':
Once the values of the coefficients and exponential terms in Eq. 1 are determined by computer fitting, the values of C, in Eq. 3 can be calculated.
The following pharmacokinetic parameters were calculated from standard equations"'":
in which V. is the volume of the central compartment; D is the intravenous dose (equal to the product of the zero-order infusion rate and the length of infusion); CI and X, are the coefficient and exponent, respectively, such that X, is the smallest of the X, values of the polyexponential equation; V. is the volume of distribution at steady state; Va,ea is the volume that, when multiplied by C in the log-linear phase, is equal to the amount of drug in the body; CL is the total plasma clearance; CL,, is the renal clearance; Ae(0-00) is the
CL,, = Ae(0-00 amount of unchanged drug recovered in the urine at time infinity; CLNR is the nonrenal clearance; 1c10 is the first-order elimination rate constant from the central compartment; and fe is the fraction of the available dose excreted unchanged in the urine. Plasma concentration-time profiles of oral bumetanide were not computer-fit because of irregular absorption profiles in many of the participants. Pertinent kinetic parameters were, therefore, calculated by a noncompartmental approach. The biologic t112 was graphically determined by linear regression with use of at least four data points from the log-linear terminal phase, and CLR was determined by division of by the plasma AUC(0-00), calculated by a combination of the trapezoidal and log-trapezoidal rules and extrapolated to infinity by Cia./X . The peak plasma concentration (C,,,R) and time to peak (tmax) after an oral dose were read directly from the plasma concentration-time curve.
Bioavailability. The extent of systemic availability of bumetanide was calculated by area ratios of oral (subscript po) and intravenous (subscript iv) dosing (Fp = AUC(0-00),/AUC(0-00)), by urinary excretion ratios (Fu = Ae(0-00),/Ae(0-a0),), and by correction for differences in CLR between oral and intravenous doses (extrapolated to infinity) as suggested by Oie and Jung':
Aelv)AUC/AUC,, + Ae,
For the calculations of Fp and Fvorr, AUC,v was determined by a combination of the trapezoidal and logtrapezoidal rules, extrapolated to infinity by CiastAl The computer-fitted and noncompartmental estimates of AUC,, differed from one another by <2%.
The mean absorption time (MAT) was used as a measure of the absorption rate of oral bumetanide by use of the noncompartmental method of statistical moments.''' MAT was calculated as the difference of mean residence times (MRT) between oral and intravenous dosing: MAT = MRT, MRT,v, where MRT equals the area under the first moment curve (AUMC; extrapolated to infinity) divided by AUC(0-ac). The AUMC was estimated by a combination of the trapezoidal and log-trapezoidal rules, extrapolated to infinity by tiast Clast/X, + Ciast/X,2. An MAT value that corrects for the time lag (tag) before drug absorption was also reported (MAT, = MAT tug). The tlag was estimated from absorption profiles using the exact VOLUME 39 NUMBER 6 Dynamics. Pharmacodynamic data were reported as the 8-hour cumulative excretion of sodium and the overall efficiency (Eff ) of the response: Eff = (AE -AE0)/AAe, where AE and AAe are the amount of sodium and drug excreted in urine, respectively, and AEo is the baseline effect over the same 8-hour period.
The relationship between the sodium excretion rate (E; in milliequivalents per minute) and urinary excretion rate of bumetanide (ER; in micrograms per minutes) was evaluated by the sigmoid Erna, E = Em ax ERs/(ER50s + ERs) + E0, where Ema is the maximum effect attributable to the drug, ER50 is the urinary excretion rate of drug producing 50% of Erna., Eo is the baseline effect, and S is the parameter influencing the slope of the dose-effect curve. The unknown parameters (Em, ER50, E0, and S) were determined *R2 = [I(Obs)2 -/(Dev)21//(Obs)2, where /(Dev)2 is the residual sum of squares.
tCORR represents the correlation between the calculated and observed plasma concentrations. Statistics. Unless otherwise indicated, data are expressed as the X -± SD. Statistical differences between the HS and CRF groups were determined by a twosample t test. Statistical differences between oral and intravenous dosing within each group were determined by a paired t test. The linear relationship between two variables was assessed by the correlation coefficient r. A P value was considered significant.
RESULTS
Semilogarithmic plots of the plasma concentrationtime curves of intravenous and oral bumetanide are shown in Figs. 1 and 2 for healthy subjects and patients with CRF, respectively. After intravenous infusion, plasma concentrations of bumetanide were fit to a biexponential equation for four data sets and to a triexpo- Table  IV . No significant differences were observed between the two groups, except for CL,, (1.71 ± 0.20 ml/ min kg in the HS group vs. 0.176 ± 0.096 ml/ min kg in the CRF group; P < 0.001), which is to be expected. The mean value for F ranged from 0.588 to 0.675 in the HS group and from 0.677 to 0.764 in the CRF group, depending on the method of calculation. Although no statistical differences were found in the biologic ti12 or CL,, in the HS and CRF groups as a function of the route of administration, CL,, was greater in seven of 10 participants after oral dosing. Therefore, the F value corrected for CLR (0.664 ± 0.112 for the HS group vs. 0.689 ± 0.149 for the CRF group) is probably the more accurate assessment of this parameter.
The Ae(0-8) and overall efficiency of bumetanideinduced natriuresis are listed in Tables V and VI, respectively. Bumetanide elicited an equivalent response in the HS and CRF groups whether taken by mouth or administered intravenously. Although the amount of sodium excreted per unit of bumetanide tended to be larger after oral dosing (Table VI) , the difference was not statistically significant at the 95% confidence level, and may reflect the small number of participants studied.
The parameters for the dose-response relationships of intravenous bumetanide are listed in Table VII . The goodness of fit was evaluated by R2 CORR and by visual examination of the residuals. In comparison with healthy subjects, patients with CRF had a significantly lower Emax (3.82 ± 1.13 mEq/min in the HS group vs.
1.09 ± 0.71 mEq/min in the CRF group; P <0.005) and an eightfold reduction in ER50 (14.0 1.-7.8 ig/min in the HS groups vs. 1.70 ± 0.87 Rg/min in the CRF group; P < 0.005). In the fitting of the sigmoid model, the first data point (i.e., the highest value for ER) was omitted for five participants (two in the HS group and three in the CRF group) because of the presence of a counterclockwise hysteresis (Figs. 4 and 5) . This phenomenon has been reported for bumetanide in dogs8'33 and humans,' and reflects the disequilibrium that can occur between the urine and effect compartments during the early periods after dosing. Dynamic parameters were not evaluated after oral dosing because insufficient data were available to define the full extent of the sigmoid-shaped curve. Nonetheless, a similar profile was observed for the dose-response relationship of bumetanide when oral and intravenous administra-VOLUME 39 NUMBER 6 Table IV . Absorption and disposition characteristics of oral bumetanide in healthy subjects and patients with CRF NS = Not significant. Table V . Natriuretic effect of bumetanide in healthy subjects and patients with CRF after oral and intravenous administration NS = Not significant. tion curves were superimposed on one another in the HS and CRF groups (Figs. 4 and 5, respectively) .
DISCUSSION
The pharmacokinetics and pharmacodynamics of bumetanide after 1 mg oral and intravenous doses have been studied by Marcantonio et al.' in patients with hepatic and renal disease. In comparison with normal subjects (n = 8), these investigators observed that patients with CRF (n = 6) had higher serum concentrations of bumetanide and that the terminal t1,2 values were significantly prolonged. They also state that the significant reduction in CL was attributable to the very low and intravenous (*) doses. The solid line represents the computer-generated regression line based on the fitted parameters in Table VII .
URINARY EXCRETION RATE (LIG/MIN)
Fig. 5. Mean ( ± SE) sodium excretion rate vs. urinary excretion rate of bumetanide in patients with CRF after oral (4)) and intravenous (*) doses. The solid line represents the computer-generated regression line based on the fitted parameters in Table VII. observed for CLR, V, and the elimination t1,2. In our study, changes in the patients' pharmacokinetics were qualitatively similar to those in the studies above,7" although these kinetic parameters were quantitatively in closer agreement to those of Marcantonio et al." for both healthy subjects and patients. This finding may be because both studies (ref. 20 and ours) involved a specific HPLC assay in which the known metabolites of bumetanide were shown not to interfere with the analysis. Likewise, the large variability in the previously reported clearances of bumetanide for healthy subjects6'7.19 probably reflects the use of different analytic methods in which drug was measured by RIA or by liquid scintillation counting after solvent extraction. In our study, the reduction in bumetanide CL, was paralleled by a concomitant reduction in nephron mass, as demonstrated by the significant positive correlation between CLR and CLcR ( Fig. 6 ; r = 0.995;P <0.001).
However, no direct correlation could be made between the corrected CLR (CLR/CLcR) of bumetanide and fu ( Fig.   7 ; r = -0.569; P > 0.05). As a result, the corrected CL, of unbound bumetanide (CLR/f CLcR) was significantly reduced in patients with CRF (143 ± 12 for subjects vs. 52.0 ± 19.6 for patients; P < 0.001). Although speculative, mechanisms consistent with this finding include the presence of capacity-limited transport, product inhibition, and competition for active secretion between bumetanide and endogenous substances in the patients with azotemia. This last hypothesis is particularly attractive because previous investigators have shown that endogenous organic acids can accu- .4
.2 VOLUME 39 NUMBER 6 Pentikainen et al.' and Halladay et al. 17 stated that the absorption of bumetanide was nearly complete (>95%) in four healthy subjects. However, their results are suspect because a nonspecific assay was used in which the drug was measured by total radioactivity in the various biologic fluids. Subsequently, Holazo et al.19 used an RIA to determine the bioavailability of bumetanide tablets in 12 normal subjects. They reported that 78% and 86% of the drug reached the systemic circulation when calculated by the area and urinary excretion methods, respectively. Using a specific HPLC assay with fluorescence detection, The lower Emax in patients with CRF (Table VII) was not surprising because their nephron mass is substantially reduced, as judged by the decrease in CL. However, based on the ER50 data alone, one might be misled to conclude that the HS group was more resistant to bumetanide therapy. Instead, a tolerance effect was probably developed to bumetanide because of an acute depletion of extracellular fluid volume and electrolytes. Although we replaced urinary losses with isovolumetric amounts of fluid by mouth, the body was apparently not replenishing the extracellular fluid volume at an equal rate. Furthermore, by the time the first fluid replacement was received (30 minutes after dosing), it may have already been too late. This hypothesis is supported by the occurrence of leg cramps in two of the healthy subjects. A similar phenomenon was also reported in a study by Hammarlund et al. ,3" in which acute tolerance developed to furosemide diuresis in rats and humans. In the study in the rat," the ER50 increased by a factor of 20 as single intravenous doses of furosemide were increased from 2.5 to 100 mg/kg. In the study in humans,' a clockwise hysteresis was noted when the oral doses were taken postprandially. In addition, the drug excretion-response curves showed parallel shifts to the right, depending on the mode of administration of furosemide. In both of these studies, the renal sensitivity to furosemide was attenuated within a very short period of time (i.e. , minutes to hours) and in an unpredictable manner. An acute volume depletion may also explain the sharp contrast of our results in healthy subjects with those of Brater et al 3.8.40 Despite the similar values for Emax, S, and E0, the ER50 was approximately 10 to 14 times greater in our study. This discrepancy may reflect the fact that urinary losses were replaced intravenously in their healthy subjects and that lower doses were used (1 mg as compared with the 5 mg doses in our study), thereby reducing the potential for volume and electrolyte depletion.
In conclusion, the bioavailability of 5 mg doses of bumetanide was approximately 65% to 70% with a variability about the mean of 15% to 20% in healthy subjects and patients with CRF. The cumulative pharmacodynamic effects of oral and intravenous doses were essentially equivalent despite the fact that a smaller C1AN PHARMACOL THER JUNE 1986 amount of drug was delivered to the site of action after oral dosing. As a result, it appears that a predictable transition from 5 mg intravenous to oral maintenance regimens of bumetanide is possible in patients with CRF. Intravenous administration should be reserved for those conditions in which a more rapid onset of action is required.
